Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 20/20 | 0.71 |
| ▸ | CA1 | P00915 | 19/20 | 0.71 |
| ▸ | CA2 | P00918 | 19/20 | 0.71 |
| ▸ | CA12 | O43570 | 10/20 | 0.71 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.68 |
| ▸ | CA7 | P43166 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26083930 | 0.94 | CA9 (0.61) | CA9CA1CA2CA12CA14 | |
| SCHEMBL19370423 | 0.93 | CA9 (0.72) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21183298 | 0.91 | CA1 (0.58) | CA9CA1CA2CA12CA14 | |
| SCHEMBL20843771 | 0.89 | CA1 (0.55) | CA9CA1CA2CA12CA14 | |
| SCHEMBL19370400 | 0.88 | CA9 (0.68) | CA9CA1CA2CA12CA14 | |
| SCHEMBL18476496 | 0.86 | CA9 (0.80) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21183305 | 0.83 | CA9 (0.61) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21728989 | 0.83 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21151146 | 0.83 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL20843768 | 0.83 | CA1 (0.51) | CA9CA1CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779602-B2 | Methods of use for CAR T cells | ENDOCYTE, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210346431-A1 | SEQUENCING METHOD FOR CAR T CELL THERAPY | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2021-11-11 | — | — | US | disclosed |
| US-20190255109-A1 | METHODS OF USE FOR CAR T CELLS | ENDOCYTE, INC. | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779602-B2 | Methods of use for CAR T cells | CD47, CD4, CD2 | CA9 499/4885CA1 829/4885CA2 2378/4885 |
| US-20190255109-A1 | METHODS OF USE FOR CAR T CELLS | CD47, CD4, CD2 | CA9 499/4885CA1 829/4885CA2 2378/4885 |
| US-20210346431-A1 | SEQUENCING METHOD FOR CAR T CELL THERAPY | CD47, MCTS1, GZMB | CA9 567/4885CA1 2463/4885CA2 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.